Cancer Research Institute (CRI) shared a post on LinkedIn:
“Israel Cancer Research Fund (ICRF) and the Cancer Research Institute have partnered on a new award, the ICRF-CRI Immunotherapy Collaborative Project Grant, given to Dr. Asaf Madi, of Tel Aviv University.
Dr. Madi was awarded $180,000 over a three-year period to support his research on refining tumor-infiltrating lymphocyte (TIL) therapy to predict response and overcome drug resistance in melanoma.
‘This collaboration reflects what progress in immunotherapy really looks like—bringing together partners, data, and discovery to tackle resistance head-on,” says CRI’s CEO, Dr. Alicia Zhou. “By understanding why some immune cells persist while others fail, Dr. Madi’s work moves us closer to making personalized cell therapies like TILs more reliable, more durable, and more transformative for patients with melanoma.’ “
More posts featuring Cancer Research Institute (CRI)